

Figure 1




Figure 2




Figure 3




Figure 4

Gene expression in LS180 tumours (dose response of 303i after 48 hours)




Figure 5

FIGURE 6(A)




FIGURE 6(B)




Figure 6

BEST AVAILABLE COPY

L I F D R H P I A A L L C Y P

160 161



Site 3

L L

168 169



Site 4

V M




FIGURE 7

BEST AVAILABLE COPY

## Tumor Model




FIGURE 8(A)

## Treatment Regime





FIGURE 8(B)




BEST AVAILABLE COPY

# Tumor Model



Tumor Seeding (i.p.)



TCS (i.p.)

Harvest Organs for In Situ

FIGURE 9(A)

## Assessment of Tumor Growth





FIGURE 9(B)

# Efficacy of Suicide Gene SPLP

BEST AVAILABLE COPY

INXC TK



CONTROL




FIGURE 9(C)

BEST AVAILABLE COPY




Figure 10

# Systemic TK303 Efficacy in the CT26 Tumor Model




FIGURE 11

TK060. Effect of Frameshift construct and TK on tumor volume




FIGURE 12